According to an NFDA official, China produces nearly 5,000 drug raw materials (APIs) providing an annual income of over 2.5 trillion yuan. Cose to 50 pharmaceutical companies are certified by European and American agencies and export APIs for over 13.5 billion US$. Problems to be solved are excess product production capacity caused by low-cost competition, export tax rebates, the pressure of RMB appreciation, and lack of extension of the value chain within China.

China Bio news release, July 13, 2017